English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A Carvedilol is a member of  BCS  class II, it has a low solubility and bioavailability. This work intends to increase the solubility of carvedilol using a multicomponent crystal method. Based on in silico investigations showed that carvedilol-arginine formed one hydrogen bond and carvedilol-glycine formed two hydrogen bonds. Compared to the solubility of pure carvedilol, CVD: GLY multicomponent crystal ratios of 1:1, 1:2, and 2:1 resulted in increases in solubility of 1.9 times, 2.6 times, and 2.5 times respectively. The solubility of the multicomponent crystals in the CVD:ARG however, did not increase. The best dissolution profile was provided by multicomponent crystal CVD: GLY (1:2), with a % dissolution of 86.03% in HCl medium pH 1.45 and 29.5% in phosphate buffer medium pH 6.8. The results of characterization included  FTIR ,  DSC ,  PXRD , and SEM evaluation of CVD: GLY multicomponent crystal (1:2) indicated the formation of a new solid crystalin phase. CVD: GLY multicomponent crystal (1:2) showing the best solubility and dissolution profile as compared to pure carvedilol.

﻿Solubility enhancement of carvedilol by multicomponent crystal approach using glycine and arginine as coformers

Solubility enhancement of carvedilol by multicomponent crystal approach using glycine and arginine as coformers